首页> 美国卫生研究院文献>Springer Open Choice >Medical isotope production research reactors and their contribution to the global xenon background
【2h】

Medical isotope production research reactors and their contribution to the global xenon background

机译:医学同位素生产研究堆及其对全球氙背景的贡献

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The Comprehensive Nuclear-Test-Ban Treaty (CTBT) bans the testing of nuclear explosive devices underground, in the atmosphere and underwater. Two main technologies, radionuclide and seismo-acoustic monitoring, are deployed in the International Monitoring System used for the verification of the CTBT. Medical isotope production from fission-based processes is the dominant contributor to a worldwide background of radioxenon. This background can make the discrimination of nuclear tests from legitimate nuclear activities very challenging. Even if emissions from medical isotope producers experienced a large reduction, there remain other important sources of radioxenon that contribute to the global background such as research reactors and nuclear power plants. Until recently, the largest producer of medical isotopes was located in Canada, at the Canadian Nuclear Laboratories (CNL) facility. The characterization of CNL emissions and its research reactor can provide valuable information for effective verification of the CTBT.
机译:《全面禁止核试验条约》(CTBT)禁止在地下,大气层和水下进行核爆炸装置的试验。在核查《全面禁试条约》的国际监测系统中,部署了两种主要技术,即放射性核素和地震声监测。基于裂变过程的医学同位素生产是全球放射性氙背景的主要贡献者。这种背景可能使对核试验与合法核活动的区别变得非常具有挑战性。即使医学同位素生产者的排放量大幅度减少,但仍有其他重要的放射性氙源对全球产生了影响,例如研究堆和核电站。直到最近,最大的医学同位素生产者位于加拿大的加拿大核实验室(CNL)设施。 CNL排放物及其研究堆的表征可为有效验证CTBT提供有价值的信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号